CE marking medical device requirements under the EU MDR in 2026

What CE marking means under the EU MDR

CE marking medical device requirements start with a practical question: can the manufacturer demonstrate that the device conforms to the applicable requirements of Regulation (EU) 2017/745, the Medical Device Regulation, before it is placed on the EU market? The CE mark is not a marketing badge or a general quality award. It is the visible sign that the manufacturer has completed the required conformity assessment, prepared an EU declaration of conformity and accepted legal responsibility for the device’s compliance.

Under the MDR, the CE marking route depends mainly on the device’s intended purpose and risk class. A low-risk Class I device may often be self-declared, while Class IIa, IIb and III devices normally require assessment by a notified body. In 2026, manufacturers also need to plan around mandatory EUDAMED use for the first four modules and the remaining MDR transition deadlines for eligible legacy devices. For broader updates on medical device rules, see our Regulatory section.

The MDR path in practice

The practical starting point is not the CE logo. It is the manufacturer’s intended purpose for the product. That intended purpose determines whether the product is a medical device, whether it is an accessory, and which MDR classification rules apply. Classification is difficult to defend if the indications, user group, operating principle, duration of contact and clinical claims are not clearly defined.

The MDR uses a risk-based structure. Devices are classified as Class I, IIa, IIb or III, with higher classes generally requiring deeper notified body scrutiny and stronger clinical evidence. Classification is performed under Annex VIII of the MDR, supported by Medical Device Coordination Group guidance. Software, implantable products, active therapeutic devices and devices that administer medicinal products can raise classification questions that should be settled early, before testing, labelling and clinical evaluation plans are fixed.

Manufacturers based outside the EU must also appoint an authorised representative in the Union. Importers and distributors have their own verification obligations, including checks related to CE marking, the EU declaration of conformity, labelling and, where applicable, UDI information. This is why CE marking is not only a manufacturer task. It also affects the compliance chain that places the device on the EU market.

Conformity assessment by risk class

Conformity assessment is the formal route used to show that the device meets the MDR’s general safety and performance requirements. The MDR sets out several conformity assessment procedures, and the correct route depends on the risk class and device type. The table below summarizes the common pattern, while leaving room for device-specific exceptions.

Device type	Typical notified body role	Practical implication
Class I, non-sterile, non-measuring and not reusable surgical instruments	Usually no notified body involvement	The manufacturer prepares the technical documentation, EU declaration of conformity and CE marking under its own responsibility.
Class I sterile, Class I measuring or Class I reusable surgical instruments	Limited notified body involvement	The notified body assessment is limited to specific aspects such as sterility, measuring function or reuse-related processes.
Class IIa	Notified body involvement normally required	The manufacturer needs an MDR conformity assessment route, quality system evidence and technical documentation review according to the applicable procedure.
Class IIb	Notified body involvement required	Clinical evidence, risk management, technical documentation and post-market planning are usually scrutinized more deeply.
Class III	Notified body involvement required, with the highest level of MDR scrutiny	Manufacturers should expect intensive review of clinical evaluation, benefit-risk determination, design evidence and post-market clinical follow-up planning.

A notified body is an organization designated by an EU Member State to perform conformity assessment tasks where third-party assessment is required. Manufacturers should verify that the notified body is designated for the relevant MDR codes and device scope. Capacity, review timelines and certificate strategy are important planning issues, but the legal foundation remains the device’s classification and the selected MDR conformity assessment procedure.

Evidence, labelling and quality system requirements

The CE mark sits on top of a much larger compliance file. The MDR expects manufacturers to maintain technical documentation that is clear, organized, searchable and capable of demonstrating conformity. This documentation is not a one-time submission folder. It must remain aligned with the device design, manufacturing process, risk management file, clinical evaluation and post-market data.

Key evidence areas usually include:

• General safety and performance requirements. Manufacturers should map each applicable Annex I requirement to objective evidence, such as design verification, validation, usability work, biological safety, electrical safety, software validation or clinical data.
• Risk management. Risks should be identified, evaluated, controlled and linked to residual risk acceptability and benefit-risk conclusions. Risk management should also connect with labelling, usability and post-market surveillance.
• Clinical evaluation. The manufacturer must evaluate clinical data to support safety, performance and clinical benefit where applicable. For many devices, post-market clinical follow-up is part of the plan for keeping that evaluation current.
• Quality management system. MDR Article 10 requires a quality management system covering regulatory strategy, responsibilities, risk management, clinical evaluation, production controls, supplier control, UDI verification, post-market surveillance, vigilance and corrective actions.
• Post-market surveillance and vigilance. Manufacturers must actively collect and assess information from the market and report serious incidents and field safety corrective actions according to MDR requirements.
• Labelling and instructions for use. Information supplied with the device must support safe use and meet language requirements in the Member States where the device is made available.

Harmonised standards can help demonstrate conformity when their references are published in the Official Journal of the European Union. Their use is generally voluntary, but an applicable harmonised standard can provide a presumption of conformity with the requirements it covers. That does not remove the manufacturer’s obligation to assess whether the standard fully addresses the device’s risks and intended purpose.

The CE marking itself must be visible, legible and indelible where it is affixed. Where a notified body is involved in the conformity assessment, the CE marking is followed by the notified body’s identification number. Manufacturers should not place markings or statements that could mislead users or authorities about the meaning of the CE mark.

2026 EUDAMED and transition issues

One of the main operational changes for CE marking in 2026 is EUDAMED. The European Commission announced that Commission Decision (EU) 2025/2371, published in the Official Journal on 27 November 2025, declared the functionality of the first four EUDAMED modules. As a result, from 28 May 2026, mandatory use applies to the Actor Registration, UDI/Devices Registration, Notified Bodies and Certificates, and Market Surveillance modules.

EUDAMED does not replace the CE marking process. Manufacturers still need the right conformity assessment, technical documentation, EU declaration of conformity and labelling controls. The change is that registration and data workflows now need to be planned as part of market access. A manufacturer may need a Single Registration Number, Basic UDI-DI strategy, device data readiness and alignment with notified body certificate records. See also: Implants.

Transition rules remain another source of confusion. Regulation (EU) 2023/607 extended MDR transition periods for certain legacy devices that were previously certified under the Medical Devices Directive or Active Implantable Medical Devices Directive. The main dates are 31 December 2027 for all Class III devices and certain Class IIb implantable devices, and 31 December 2028 for other Class IIb devices, Class IIa devices, and Class I sterile or measuring devices.

Those extensions are conditional. A legacy device must continue to comply with the former directive, must not undergo significant changes in design or intended purpose, must not present an unacceptable health or safety risk, and the manufacturer must have taken required MDR transition steps within the regulatory deadlines. New devices cannot use the old directives as a shortcut. If a device is new to the market, the MDR route applies.

Practical checklist before affixing the CE mark

A useful way to manage CE marking is to treat it as a staged evidence project rather than a final artwork task. The following sequence reflects the logic manufacturers commonly need under the MDR:

1. Define the intended purpose, indications, users, patient population, operating principle and claims.
2. Confirm that the product qualifies as a medical device or accessory under the MDR.
3. Apply the Annex VIII classification rules and document the rationale.
4. Identify the correct conformity assessment route and whether a notified body is required.
5. Build or update the quality management system so it covers MDR-specific obligations.
6. Prepare technical documentation under Annexes II and III, including design, manufacturing, verification, validation and post-market surveillance content.
7. Complete the general safety and performance requirements checklist with evidence references.
8. Prepare the clinical evaluation and, where needed, the post-market clinical follow-up plan.
9. Set up labelling, UDI, language, authorised representative, importer and distributor controls.
10. Complete conformity assessment, draw up the EU declaration of conformity, register required data and affix the CE marking correctly.

Common delays often come from treating clinical evaluation, UDI, language requirements or post-market surveillance as late-stage tasks. Under the MDR, these elements influence the technical file and notified body review, so they should be built into the project plan from the beginning.

Frequently asked questions

Is CE marking the same as EU approval?

Not exactly. CE marking shows that the manufacturer declares conformity with applicable EU requirements after completing the required conformity assessment. For many medical devices, that assessment includes a notified body. It is not the same concept as a centralized premarket approval issued by a single EU agency.

Can a Class I medical device be self-certified?

Many Class I devices can be CE marked without notified body involvement, but there are important exceptions. Class I sterile devices, measuring devices and reusable surgical instruments require notified body assessment for the relevant limited aspects. The manufacturer still remains responsible for the full MDR compliance file.

Does a CE-marked device need post-market surveillance?

Yes. CE marking is not the end of compliance. The MDR requires a post-market surveillance system proportionate to the device and risk class. Manufacturers must use market feedback, complaints, vigilance information and other data to keep risk management, clinical evaluation and technical documentation current.

Do custom-made medical devices carry a CE mark?

Custom-made devices follow a different MDR route and generally do not bear the CE marking. They require documentation and a statement under the MDR framework, but they should not be treated as standard serial-production devices for CE marking purposes.

What is the most important 2026 CE marking planning point?

For many manufacturers, the key 2026 planning point is the link between CE marking work and EUDAMED readiness. From 28 May 2026, the first four EUDAMED modules are mandatory, so registration data, UDI strategy, actor registration and certificate information should be aligned with the conformity assessment plan.